Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 1835 results for carers

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

  2. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

  3. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

  4. Methods research areas

    NICE priority methodological research areas.

  5. Learning disabilities: register (IND119)

    This indicator covers establishing and maintaining a register of patients with learning disabilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM73

  6. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  7. Stroke and ischaemic attack: review 6 months after discharge (IND31)

    This indicator covers the proportion of people who had a stroke who are reviewed within 6 months of being discharged from hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG48

  8. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (HTG149)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

  9. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

  10. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  11. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

  12. Insertion of endobronchial nitinol coils to improve lung function in emphysema (HTG370)

    Evidence-based recommendations on insertion of endobronchial nitinol coils to improve lung function in emphysema. This involves inserting coils to reduce airflow to damaged parts of the lung.

  13. Superficial venous arterialisation for chronic limb threatening ischaemia (HTG637)

    Evidence-based recommendations on superficial venous arterialisation for chronic limb threatening ischaemia in adults. This involves joining an artery in the lower leg to a large vein to divert blood flow through the vein towards the foot, bypassing the blocked arteries.

  14. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

  15. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.